Leerink Partners Boosts Vaxcyte (NASDAQ:PCVX) Price Target to $153.00

Vaxcyte (NASDAQ:PCVX) had its target price hoisted by Leerink Partners from $106.00 to $153.00 in a research note issued to investors on Tuesday morning, Benzinga reports. Leerink Partners currently has an outperform rating on the stock.

Several other research analysts also recently issued reports on PCVX. BTIG Research upped their price objective on Vaxcyte from $98.00 to $160.00 and gave the company a buy rating in a research note on Tuesday. Needham & Company LLC upped their price target on shares of Vaxcyte from $95.00 to $140.00 and gave the company a buy rating in a research report on Tuesday. Finally, Cantor Fitzgerald reiterated an overweight rating on shares of Vaxcyte in a report on Thursday, June 20th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of Buy and an average price target of $131.83.

Vaxcyte Price Performance

NASDAQ PCVX opened at $111.58 on Tuesday. The business has a fifty day moving average price of $81.80 and a two-hundred day moving average price of $73.53. The stock has a market capitalization of $12.14 billion, a PE ratio of -26.07 and a beta of 0.97. Vaxcyte has a fifty-two week low of $44.20 and a fifty-two week high of $119.27.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.12). During the same period in the prior year, the business earned ($0.70) earnings per share. As a group, sell-side analysts expect that Vaxcyte will post -4.33 earnings per share for the current year.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 10,000 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $111.93, for a total value of $1,119,300.00. Following the completion of the sale, the chief operating officer now directly owns 207,503 shares of the company’s stock, valued at $23,225,810.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, SVP Mikhail Eydelman sold 1,667 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $76.37, for a total value of $127,308.79. Following the sale, the senior vice president now owns 30,826 shares of the company’s stock, valued at $2,354,181.62. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Jim Wassil sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $111.93, for a total transaction of $1,119,300.00. Following the completion of the transaction, the chief operating officer now directly owns 207,503 shares of the company’s stock, valued at $23,225,810.79. The disclosure for this sale can be found here. Insiders have sold a total of 85,283 shares of company stock worth $7,271,218 over the last three months. 3.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Vaxcyte

A number of large investors have recently modified their holdings of the company. Truist Financial Corp raised its holdings in shares of Vaxcyte by 12.7% during the 4th quarter. Truist Financial Corp now owns 8,805 shares of the company’s stock valued at $553,000 after buying an additional 991 shares in the last quarter. Natixis Advisors L.P. purchased a new position in shares of Vaxcyte during the fourth quarter worth approximately $881,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Vaxcyte by 2.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 730,438 shares of the company’s stock worth $45,872,000 after acquiring an additional 17,570 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of Vaxcyte by 1.7% in the 4th quarter. Principal Financial Group Inc. now owns 22,008 shares of the company’s stock valued at $1,382,000 after purchasing an additional 376 shares in the last quarter. Finally, First Turn Management LLC bought a new position in shares of Vaxcyte during the 4th quarter valued at $22,453,000. 96.78% of the stock is currently owned by institutional investors.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.